The first comprehensive retrospective analysis of a large multicentric ER+/HER2- breast cancer cohort by Desmedt et al. [117] reported that TIL levels in ILC were statistically significantly lower than those of IDC, with a median level of 5%. The gene discussed is ESR1; the disease is breast carcinoma.